Rosandra N. Kaplan

Center for Cancer Research — United States

Medicine · Health Sciences

32h-index16.2kcitations294works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(62), PI3K/AKT/mTOR signaling in cancer(43), Childhood Cancer Survivors' Quality of Life(42), Chronic Myeloid Leukemia Treatments(42), Immune cells in cancer(38)

Publications294 total

Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy
2026Open Access
Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Uncovering the key mediators of monocyte trogocytosis of cancer cells and implications on monocyte function, antibody efficacy and antigen presentation 4363
The Journal of Immunology·2025Open Access
521 Correlative analysis of a phase I study of autologous activated NK Cells ± rhIL-15 in children and young adults with refractory solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
319 Genetically engineered myeloid cell therapy systemically reconfigures the myeloid compartment to promote anti-tumor immunity
Regular and Young Investigator Award Abstracts·2025Open Access
738 Bit by bit: Uncovering the regulators of monocyte-tumor trogocytosis
Regular and Young Investigator Award Abstracts·2025Open Access
351 Development of human genetically engineered myeloid cells (GEMys) for first-in-human clinical trial
Regular and Young Investigator Award Abstracts·2025Open Access
267 Pre-clinical evaluation of a new B7-H3 CAR in a human glioblastoma model
Regular and Young Investigator Award Abstracts·2025Open Access
Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout
Cancers·2025· 1 citedOpen Access
Identifying caregiver-reported modifiable barriers to pediatric oncology clinical trial enrollment and participation
2025Open Access
Supplementary Table 3 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
2025Open Access
Table 4 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
2025Open Access
page 1 of 15Next →

Frequent Co-authors

David Lyden(14), John Glod(9), Crystal L. Mackall(8), Brigitte C. Widemann(8), Jack F. Shern(6), Markku Miettinen(6), Javed Khan(6), Jacqueline Bromberg(5), Meera Murgai(5), Terry J. Fry(5), Héctor Peinado(4), Irina Matei(4), Shahin Rafii(4), Bethan Psaila(4), Steven L. Highfill(4), Amber Giles(4), Melinda S. Merchant(4), Jun S. Wei(4), Joanne Derdak(4), Eva Dombi(4)